Regulation of Immune Responses by Prostaglandin E2

PGE2, an essential homeostatic factor, is also a key mediator of immunopathology in chronic infections and cancer. The impact of PGE2 reflects the balance between its cyclooxygenase 2-regulated synthesis and 15-hydroxyprostaglandin dehydrogenase-driven degradation and the pattern of expression of PGE2 receptors. PGE2 enhances its own production but suppresses acute inflammatory mediators, resulting in its predominance at late/chronic stages of immunity. PGE2 supports activation of dendritic cells but suppresses their ability to attract naive, memory, and effector T cells. PGE2 selectively suppresses effector functions of macrophages and neutrophils and the Th1-, CTL-, and NK cell-mediated type 1 immunity, but it promotes Th2, Th17, and regulatory T cell responses. PGE2 modulates chemokine production, inhibiting the attraction of proinflammatory cells while enhancing local accumulation of regulatory T cells cells and myeloid-derived suppressor cells. Targeting the production, degradation, and responsiveness to PGE2 provides tools to modulate the patterns of immunity in a wide range of diseases, from autoimmunity to cancer.

[1]  K. Odunsi,et al.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.

[2]  R. Edwards,et al.  Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.

[3]  W. Germeraad,et al.  Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. , 2011, Blood.

[4]  S. H. van der Burg,et al.  M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells , 2011, The Journal of Immunology.

[5]  B. Brüne,et al.  Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2 , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  V. Cerundolo,et al.  Prostaglandin E2 suppresses the differentiation of retinoic acid–producing dendritic cells in mice and humans , 2011, The Journal of experimental medicine.

[7]  S. Narumiya,et al.  Prostaglandin E2–prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression , 2011, Proceedings of the National Academy of Sciences.

[8]  W. Fellows-Mayle,et al.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. , 2011, Cancer research.

[9]  L. Crofford,et al.  Genetic deletion of mPGES-1 abolishes PGE2 production in murine dendritic cells and alters the cytokine profile, but does not affect maturation or migration. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[10]  M. Norval,et al.  Ultraviolet Irradiation of Mice Reduces the Competency of Bone Marrow-Derived CD11c+ Cells via an Indomethacin-Inhibitable Pathway , 2010, The Journal of Immunology.

[11]  E. White,et al.  Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. , 2010, The American journal of pathology.

[12]  P. Serafini Editorial: PGE2‐producing MDSC: a role in tumor progression? , 2010, Journal of leukocyte biology.

[13]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[14]  K. Subbaramaiah,et al.  UV Radiation Inhibits 15-Hydroxyprostaglandin Dehydrogenase Levels in Human Skin: Evidence of Transcriptional Suppression , 2010, Cancer Prevention Research.

[15]  L. Zon,et al.  Newly emerging roles for prostaglandin E2 regulation of hematopoiesis and hematopoietic stem cell engraftment , 2010, Current opinion in hematology.

[16]  S. Narumiya,et al.  Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[17]  A. Panigrahy,et al.  IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitis , 2010, The Journal of experimental medicine.

[18]  T. Standiford,et al.  A Role for IL-1 Receptor-Associated Kinase-M in Prostaglandin E2-Induced Immunosuppression Post-Bone Marrow Transplantation , 2010, The Journal of Immunology.

[19]  J. Kawabe,et al.  Roles of prostanoids in the pathogenesis of cardiovascular diseases. , 2010, International angiology : a journal of the International Union of Angiology.

[20]  C. Wood,et al.  Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. , 2010, The American journal of pathology.

[21]  T. Reinhart,et al.  PGE2 Transiently Enhances DC Expression of CCR7 but Inhibits the Ability of DCs to Produce CCL19 and Attract Naïve T cells , 2010 .

[22]  S. Rivest Interactions between the immune and neuroendocrine systems. , 2010, Progress in brain research.

[23]  J. Kirkwood,et al.  Independent Regulation of Chemokine Responsiveness and Cytolytic Function versus CD8+ T Cell Expansion by Dendritic Cells , 2009, The Journal of Immunology.

[24]  J. Vieweg,et al.  Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer , 2009, The Journal of Immunology.

[25]  M. Bertagnolli,et al.  15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors , 2009, Proceedings of the National Academy of Sciences.

[26]  T. Mcclanahan,et al.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling , 2009, The Journal of experimental medicine.

[27]  D. Bartlett,et al.  Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. , 2008, Cancer research.

[28]  J. Nyström,et al.  Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. , 2008, Cancer research.

[29]  D. Ganea,et al.  In Vitro Differentiation of Dendritic Cells in the Presence of Prostaglandin E2 Alters the IL-12/IL-23 Balance and Promotes Differentiation of Th17 Cells1 , 2008, The Journal of Immunology.

[30]  Chu Chen,et al.  Cyclooxygenase-2 in synaptic signaling. , 2008, Current pharmaceutical design.

[31]  J. Frelinger,et al.  Respiratory Francisella tularensis Live Vaccine Strain Infection Induces Th17 Cells and Prostaglandin E2, Which Inhibits Generation of Gamma Interferon-Positive T Cells , 2008, Infection and Immunity.

[32]  D. Ganea,et al.  PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. , 2008, Blood.

[33]  D. Aronoff,et al.  Activation of Phosphatase and Tensin Homolog on Chromosome 10 Mediates the Inhibition of FcγR Phagocytosis by Prostaglandin E2 in Alveolar Macrophages1 , 2007, The Journal of Immunology.

[34]  T. Whiteside,et al.  Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. , 2007, Cancer research.

[35]  D. Nie,et al.  Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.

[36]  G. Taylor,et al.  Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3 , 2007, Proceedings of the National Academy of Sciences.

[37]  D. Aronoff,et al.  Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. , 2007, American journal of respiratory cell and molecular biology.

[38]  R. Tuma,et al.  The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23→IL-17 Axis1 , 2007, The Journal of Immunology.

[39]  P. Sinha,et al.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.

[40]  P. Rodriguez,et al.  Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[41]  P. Sinha,et al.  Prostaglandin E 2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells , 2007 .

[42]  R. Steinman,et al.  Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. , 2006, Blood.

[43]  D. Aronoff,et al.  Critical Role of Prostaglandin E2 Overproduction in Impaired Pulmonary Host Response following Bone Marrow Transplantation1 , 2006, The Journal of Immunology.

[44]  C. Figdor,et al.  A Critical Role for Prostaglandin E2 in Podosome Dissolution and Induction of High-Speed Migration during Dendritic Cell Maturation1 , 2006, The Journal of Immunology.

[45]  E. Aandahl,et al.  FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism1 , 2006, The Journal of Immunology.

[46]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[47]  D. Besselsen,et al.  Short‐term dietary administration of celecoxib enhances the efficacy of tumor lysate‐pulsed dendritic cell vaccines in treating murine breast cancer , 2006, International journal of cancer.

[48]  G. Caron,et al.  Histamine and prostaglandin E2 up‐regulate the production of Th2‐attracting chemokines (CCL17 and CCL22) and down‐regulate IFN‐γ‐induced CXCL10 production by immature human dendritic cells , 2006, Immunology.

[49]  H. Lau,et al.  Prostaglandin E2 potentiates the immunologically stimulated histamine release from human peripheral blood‐derived mast cells through EP1/EP3 receptors , 2006, Allergy.

[50]  S. Albelda,et al.  Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine , 2006, Clinical Cancer Research.

[51]  L. Yao,et al.  Prostaglandin E2 promotes degranulation‐independent release of MCP‐1 from mast cells , 2006, Journal of leukocyte biology.

[52]  Simon C Watkins,et al.  Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. , 2005, Cancer research.

[53]  Simon C Watkins,et al.  IL-18–induced CD83+CCR7+ NK helper cells , 2005, The Journal of experimental medicine.

[54]  M. Albert,et al.  A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. , 2005, Blood.

[55]  Li Zhu,et al.  Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.

[56]  J. Regan,et al.  Differential Regulation of Phosphorylation of the cAMP Response Element-Binding Protein after Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 , 2005, Molecular Pharmacology.

[57]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[58]  A. Devillers,et al.  Biodistribution of radiolabelled human dendritic cells injected by various routes , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  S. Lippman,et al.  Advances in the biology of lung cancer chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  H. Tai,et al.  15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal Cancer* , 2005, Journal of Biological Chemistry.

[61]  M. Dohadwala,et al.  Prostaglandin E2-Dependent Enhancement of Tissue Inhibitors of Metalloproteinases-1 Production Limits Dendritic Cell Migration through Extracellular Matrix1 , 2004, The Journal of Immunology.

[62]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[63]  R. Breyer,et al.  Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. , 2004, Pharmacology & therapeutics.

[64]  D. Aronoff,et al.  Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated Increase in Intracellular Cyclic AMP12 , 2004, The Journal of Immunology.

[65]  W. Walker,et al.  Prostaglandin E2 is a potent regulator of interleukin‐12‐ and interleukin‐18‐induced natural killer cell interferon‐γ synthesis , 2004, Immunology.

[66]  Raja' M. Abdel-Majid,et al.  Prostaglandin E2 Induces Degranulation-Independent Production of Vascular Endothelial Growth Factor by Human Mast Cells1 , 2004, The Journal of Immunology.

[67]  C. Vancheri,et al.  The lung as a privileged site for the beneficial actions of PGE2. , 2004, Trends in immunology.

[68]  L. Neckers,et al.  IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesis , 2003 .

[69]  J. Abe,et al.  Thrombospondin 1 Is an Autocrine Negative Regulator of Human Dendritic Cell Activation , 2003, The Journal of experimental medicine.

[70]  H. Young,et al.  Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. , 2003, Blood.

[71]  E. Butcher,et al.  Chemokines in the systemic organization of immunity , 2003, Immunological reviews.

[72]  J. Morrow,et al.  Formation of Prostaglandins E2 and D2 via the Isoprostane Pathway , 2003, Journal of Biological Chemistry.

[73]  J. Regan,et al.  Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.

[74]  M. Huang,et al.  Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  Yun-Jin Jung,et al.  IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[77]  Naphtali Abudarham,et al.  Prostaglandin E2 Suppresses NK Activity In Vivo and Promotes Postoperative Tumor Metastasis in Rats , 2003, Annals of Surgical Oncology.

[78]  R. Förster,et al.  Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. , 2002, Blood.

[79]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[80]  H. Tai,et al.  Prostaglandin catabolizing enzymes. , 2002, Prostaglandins & other lipid mediators.

[81]  C. Meijer,et al.  Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.

[82]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[83]  J. Regan,et al.  Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.

[84]  P. Kalinski,et al.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. , 2001, Blood.

[85]  H. Pauels,et al.  Prostaglandins, but not tumor‐derived IL‐10, shut down concomitant tumor‐specific CTL responses during murine plasmacytoma progression , 2001, International journal of cancer.

[86]  Xinchun Zhou,et al.  Prostaglandin E2 Suppressed IL-15-Mediated Human NK Cell Function Through Down-Regulation of Common γ-Chain1 , 2001, The Journal of Immunology.

[87]  K. Gomi,et al.  Prostaglandin E2 Selectively Enhances the IgE-Mediated Production of IL-6 and Granulocyte-Macrophage Colony-Stimulating Factor by Mast Cells Through an EP1/EP3-Dependent Mechanism1 , 2000, The Journal of Immunology.

[88]  L. Moldawer,et al.  Autoregulation of Human Monocyte-Derived Dendritic Cell Maturation and IL-12 Production by Cyclooxygenase- 2-Mediated Prostanoid Production1 , 2000, The Journal of Immunology.

[89]  B. Wollenberg,et al.  Tumor cell‐derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac‐1 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  H. Castro-Faria-Neto,et al.  Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages , 2000, Nature.

[91]  Li Zhu,et al.  Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.

[92]  P. Kalinski,et al.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.

[93]  P. Kalinski,et al.  The paradigm of type 1 and type 2 antigen‐presenting cells. Implications for atopic allergy , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[94]  J. Finke,et al.  Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. , 1999, Blood.

[95]  M. Lazdunski,et al.  Receptors for a growing family of secreted phospholipases A2. , 1999, Trends in pharmacological sciences.

[96]  Y. Yu,et al.  Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism. , 1998, Journal of immunology.

[97]  R. Seder,et al.  Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. , 1998, Journal of immunology.

[98]  P. Kalinski,et al.  Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.

[99]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[100]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[101]  H. Klocker,et al.  Prostaglandin E2 and Tumor Necrosis Factor ␣ Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997 .

[102]  P. Kalinski,et al.  IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. , 1997, Journal of immunology.

[103]  A. Ichikawa,et al.  Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. , 1996, Molecular pharmacology.

[104]  J. Forrester,et al.  Prostaglandin E2 and monoclonal antibody to lymphocyte function‐associated antigen‐1 differentially inhibit migration of T lymphocytes across microvascular retinal endothelial cells in rat , 1996, Immunology.

[105]  T. Shimamura,et al.  An essential role of prostaglandin E on mouse mast cell induction. , 1995, Journal of immunology.

[106]  L. Aarden,et al.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production , 1995, The Journal of experimental medicine.

[107]  D. Carvajal,et al.  Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist , 1995, European journal of immunology.

[108]  J. Regan,et al.  Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. , 1994, Molecular pharmacology.

[109]  N. Oppenheimer-Marks,et al.  Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. , 1994, Journal of immunology.

[110]  P. Kalinski,et al.  Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. , 1993, Journal of immunology.

[111]  Y. Sugimoto,et al.  Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. , 1993, The Journal of biological chemistry.

[112]  A. Lanzavecchia,et al.  Role of cAMP in regulating cytotoxic T lymphocyte adhesion and motility , 1993, European journal of immunology.

[113]  Y. Sugimoto,et al.  Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. , 1992, The Journal of biological chemistry.

[114]  R. L. Roper,et al.  A new view of prostaglandin E regulation of the immune response. , 1991, Immunology today.

[115]  M. Betz,et al.  Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. , 1991, Journal of immunology.

[116]  P. García-Peñarrubia,et al.  Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity , 1989, The Journal of experimental medicine.

[117]  P. Lala,et al.  Prostaglandin E2‐Mediated Inactivation of Various Killer Lineage Cells by Tumor‐Bearing Host Macrophages , 1988, Journal of leukocyte biology.

[118]  A. López-Rivas,et al.  Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells , 1988, European journal of immunology.

[119]  P. Lala,et al.  Suppression of lymphocyte alloreactivity by early gestational human decidua. II. Characterization of the suppressor mechanisms. , 1988, Cellular immunology.

[120]  P. Lipsky,et al.  Inhibition of human B cell responsiveness by prostaglandin E2. , 1987, Journal of immunology.

[121]  M. Plaut,et al.  The role of cyclic AMP in modulating cytotoxic T lymphocytes. II. Sequential changes during culture in responsiveness of cytotoxic lymphocytes to cyclic AMP-active agents. , 1983, Journal of immunology.

[122]  I. Gigli,et al.  Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation. , 1983, The Journal of investigative dermatology.

[123]  U. Förstermann,et al.  Elimination from the circulation of cats of 6‐keto‐prostaglandin E1 compared with prostaglandins E2 and I2 , 1983, The Journal of pharmacy and pharmacology.

[124]  F. Bettens,et al.  Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. , 1983, Journal of immunology.

[125]  R. Herberman,et al.  Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. , 1983, Journal of immunology.

[126]  D. Evans,et al.  Effect of prostaglandins on elicitation of anti-viral-cytolytic activity. , 1982, Immunology letters.

[127]  Bankhurst Ad The modulation of human natural killer cell activity by prostaglandins. , 1982 .

[128]  A. Bankhurst The modulation of human natural killer cell activity by prostaglandins. , 1982, Journal of clinical & laboratory immunology.

[129]  C. Carini,et al.  Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. , 1981, British Journal of Cancer.

[130]  F. Fitzpatrick,et al.  The stability of 13,14-dihydro-15 keto-PGE2. , 1980, Prostaglandins.

[131]  R. Smith Modulation of phagocytosis by and lysosomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglindins. , 1977, The Journal of pharmacology and experimental therapeutics.